成人呼吸道合胞病毒风险评估:超越年龄的疫苗推荐意义
该研究在纽约州罗切斯特和纽约市纳入2017-2020年三个冬季≥18岁经PCR确诊RSV住院的成人,按4个年龄组估计基于人群的发病率。合并充血性心力衰竭、冠心病、慢阻肺、糖尿病的成人RSV住院风险显著升高(发病率比分别为13.66、8.24、5.85、5.35)。18-44岁和45-64岁黑人成人RSV住院发病率分别较其他种族高2.5倍和8倍,西班牙裔各年龄层高2-3倍。慢阻肺使ICU入住或院内死亡复合风险升高1.9倍(97.5%CI 1.27-2.68),慢阻肺和心衰均增加6个月全因死亡风险,年龄≥65岁与两种结局均无关。
要点
- 合并充血性心力衰竭的成人RSV住院风险最高(发病率比13.66),其次为冠心病8.24、慢阻肺5.85、糖尿病5.35。
- 慢阻肺使ICU入住或院内死亡复合风险升高1.9倍(97.5%CI 1.27-2.68),慢阻肺与心衰均增加6个月全因死亡风险。
- 18-44岁黑人成人RSV住院发病率较其他种族高2.5倍,45-64岁高8倍;西班牙裔各年龄层高2-3倍。
- 年龄≥65岁与ICU入住/院内死亡及6个月全因死亡均无关。
- 哮喘、肥胖、免疫抑制在≤65岁年轻成人中更常见。
适用人群与场景
- ≥18岁成人,2017-2020年三个冬季因PCR确诊RSV住院,招募于纽约州罗切斯特和纽约市。
- 按年龄分为18-44、45-64、65-74、≥75岁四组,按种族和族裔估计人群发病率。
研究设计与关键结果
- 研究类型:基于人群的发病率评估研究,纳入三个冬季(2017-2020)PCR确诊RSV住院成人。
- 合并充血性心力衰竭、冠心病、慢阻肺、糖尿病的成人RSV住院风险升高,发病率比分别为13.66、8.24、5.85、5.35。
- 18-44岁黑人成人RSV住院发病率较其他种族高2.5倍,45-64岁高8倍;西班牙裔各年龄层高2-3倍。
- 慢阻肺使ICU入住或院内死亡复合风险升高1.9倍(97.5%CI 1.27-2.68)。
- 慢阻肺和充血性心力衰竭均增加6个月全因死亡风险;年龄≥65岁与两种结局均无关。
- 哮喘、肥胖、免疫抑制在≤65岁年轻成人中更常见。
证据类型、等级与局限
- 证据类型:基于人群的观察性研究(三个冬季,2017-2020)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,未来RSV疫苗推荐应考虑基础疾病和种族与族裔差异对年龄相关RSV住院的影响。
- 原文未据此给出具体临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Respiratory syncytial virus (RSV) causes hospitalization in older adults and those with preexisting medical conditions. Three RSV vaccines are now licensed for all adults but not recommended for persons age <60 years with risk factors for RSV hospitalization. We therefore assessed the relationship of preexisting medical conditions to age-specific RSV hospitalization incidence and severe outcomes.
METHODS: Adults age ≥18 years hospitalized over 3 winters (2017-2020) with polymerase chain reaction-confirmed RSV were enrolled in Rochester and New York City, NY. Population-based incidence was estimated by race and ethnicity for 4 age groups: 18-44, 45-64, 65-74, and ≥75 years. A general linear model assessed variables associated with 2 outcomes: (1) composite of intensive care unit admission and/or in-hospital mortality and (2) all-cause 6-month mortality.
RESULTS: Adults of all ages with congestive heart failure (CHF), coronary artery disease, chronic obstructive pulmonary disease (COPD), and diabetes were more likely to be hospitalized with RSV (incidence rate ratio, 13.66, 8.24, 5.85, and 5.35, respectively), and asthma, obesity, and immunosuppression were more prevalent among younger adults age ≤65 years. Mean annual RSV hospitalization incidence was 2.5-fold higher for Black adults age 18-44 years and 8-fold higher for those age 45-64 years compared with other races. Hispanic adults had a 2-3-fold higher incidence of hospitalization in each age stratum compared with non-Hispanics. COPD conferred a 1.9-fold higher risk of intensive care unit admission or in-hospital mortality (97.5% CI, 1.27-2.68), and both COPD and CHF increased risk of 6-month all-cause mortality. Age ≥65 years was not associated with either outcome.
CONCLUSIONS: Future RSV vaccine recommendations should consider the impact of preexisting conditions and racial and ethnic differences in age-related RSV hospitalization.
参考来源
- Branche AR, Falsey AR, Saiman L, et al. Respiratory Syncytial Virus Risk Assessment in Adults: Implications for Vaccine Recommendations Beyond Age. Open Forum Infect Dis. 2025. PMID: 40698030. doi:10.1093/ofid/ofaf394
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。